节后,和铂医药再次抛出一项重磅合作。据其公告,和铂医药与Solstice Oncology(一家由多个头部风险投资机构联合创立的临床阶段生物技术公司)达成授权协议及股权合作,授予对方一款临床阶段候选产品HBM4003在大中华区以外地区的独家开发及商业化权益。这场“现金+股权”的创新合作,或将成为铂医药全球化布局的又一里程碑。 12亿美元BD出海 根据协议条款,和铂医药有资格获得价值超过1.05...
Source Link节后,和铂医药再次抛出一项重磅合作。据其公告,和铂医药与Solstice Oncology(一家由多个头部风险投资机构联合创立的临床阶段生物技术公司)达成授权协议及股权合作,授予对方一款临床阶段候选产品HBM4003在大中华区以外地区的独家开发及商业化权益。这场“现金+股权”的创新合作,或将成为铂医药全球化布局的又一里程碑。 12亿美元BD出海 根据协议条款,和铂医药有资格获得价值超过1.05...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.